Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Personalis Inc (PSNL) USD0.0001

Sell:$9.77 Buy:$9.80 Change: $0.53 (5.72%)
Market closed |  Prices as at close on 10 December 2019 | Switch to live prices |
Sell:$9.77
Buy:$9.80
Change: $0.53 (5.72%)
Market closed |  Prices as at close on 10 December 2019 | Switch to live prices |
Sell:$9.77
Buy:$9.80
Change: $0.53 (5.72%)
Market closed |  Prices as at close on 10 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Personalis, Inc. is a cancer genomics company. The Company is focused on the development of therapies by providing molecular data about each patient’s cancer and immune response. The Company has designed NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. It also report on the entire transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

Contact details

Address:
1330 Obrien Dr
MENLO PARK
94025-1436
United States
Telephone:
+1 (650) 7521300
Website:
www.personalis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PSNL
ISIN:
US71535D1063
Market cap:
$293.60 million
Shares in issue:
31.23 million
Sector:
Life Sciences Tools & Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John West
    Chief Executive Officer, Director
  • Aaron Tachibana
    Chief Financial Officer
  • Richard Chen
    Chief Science Officer
  • Carol Tillis
    Vice President - Finance and Administration
  • Michael Fitzpatrick
    Vice President - Worldwide Sales
  • Christian Haudenschild
    Vice President - Genomic Services

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.